权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A Drug Delivery Strategy for Targeted Therapy of Chronic Lymphocytic Leukemia

慢性淋巴细胞白血病靶向治疗的给药策略

基本信息

批准号：
9898332
负责人：
CHRISTOPH RADER
金额：
$ 57.5万
依托单位：
SCRIPPS FLORIDA
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-06-12 至 2023-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9898332
关键词：
Address Affect Antibodies Antibody-drug conjugates Antigens Autologous B lymphoid malignancy B-Lymphocytes Binding Biological C-terminal Cell Line Cell surface Cells Cessation of life Chemicals Chronic Lymphocytic Leukemia Combination Drug Therapy Confocal Microscopy Cytotoxic agent DNA Development Drug Delivery Systems Drug Kinetics Drug Targeting Engineering Fc Immunoglobulins Female Fluorescein Funding Goals Human IgG1 Immunoglobulin G Immunoglobulin M In Vitro Indolent Investigation Lysine Lysosomes Malignant - descriptor Malignant Neoplasms Mediating Molecular Monoclonal Antibodies Mus Mutation Names Oryctolagus cuniculus Pathway interactions Patients Peripheral Blood Mononuclear Cell Phage Display Pharmaceutical Preparations Property Protein Fragment ROR1 gene Research Selenocysteine Series Site Specificity Surface Antigens T-Lymphocyte Technology Testing Therapeutic Intervention Tissues Toxic effect Tubulin Validation Woman Work Xenograft procedure base cancer therapy chronic lymphocytic leukemia cell clinical translation combinatorial cytotoxic cytotoxicity design dimer experimental study improved in vivo in vivo Model inhibitor/antagonist kinase inhibitor leukemia male men mouse model new therapeutic target next generation novel overexpression pre-clinical prototype receptor response selective expression small molecule targeted treatment trafficking

项目摘要

This project generates, validates, and delivers novel antibody-drug conjugates (ADCs) that are designed to selectively and potently eradicate chronic lymphocytic leukemia (CLL), the most common leukemia in the U.S., without affecting healthy cells and tissues. CLL is an indolent yet incurable B-cell malignancy that afflicts more than 150,000 men and women and causes more than 4,500 deaths per year in the U.S. alone. There are currently no treatment options for CLL that allow for selective targeting of malignant B cells and that spare healthy B cells and other healthy cells and tissues. With this Premise, the project is built on the Hypothesis that the Fcµ receptor FCMR, on its own or in combination with other selectively expressed CLL cell surface antigens, can mediate rapid and effective cellular entry of cytotoxic drugs for potent and specific therapeutic intervention. Two independent Specific Aims will be pursued to rigorously test this hypothesis. In Aim 1, a series of molecularly defined ADCs will be generated that deliver and release a highly cytotoxic tubulin inhibitor and a highly cytotoxic DNA-targeting drug, on their own or in combination, via the FCMR internalization and trafficking pathway. These ADCs will be based on the selenomab-drug conjugate platform which utilizes an engineered selenocysteine residue for site-specific drug conjugation. By extensive validation in vitro, ex vivo, and in vivo, a panel of FCMR-targeting selenomab-drug conjugates will be assessed for their stability, specificity, potency, toxicity, and pharmacokinetics. Aim 2 builds on a novel dual variable domain (DVD)-IgG1- based ADC platform that utilizes a unique reactive lysine residue for site-specific drug conjugation. DVD-IgM- based ADCs that can simultaneously engage FCMR and a second CLL cell surface antigen will be built and extensively validated. In addition to a highly modular research strategy that systematically compares different targets, different antibodies, different antibody formats, different linkers, and different drugs, the ex vivo and in vivo experiments in both Specific Aims will be based on peripheral blood mononuclear cells from male and female CLL patients rather than on cell lines to collectively achieve Robust and Unbiased Results toward delivering a candidate for advanced preclinical investigations and eventual clinical translation. Throughout this campaign, conceptually novel biological and chemical components with broad applicability to next-generation ADCs for cancer therapy will be developed.

该项目生成，验证和提供新的抗体-药物偶联物（adc），旨在